Results 191 to 200 of about 73,057 (319)

Recurrent haemorrhage, due to vitamin K‐dependent coagulopathy, as the primary presenting complaint in a dog with naturally occurring hypoadrenocorticism

open access: yesVeterinary Record Case Reports, Volume 14, Issue 1, February 2026.
Abstract A 5‐year‐old male neutered standard poodle, presented with recurrent gingival margin haemorrhage and associated prolongations in prothrombin time and activated partial thromboplastin time, with repeatable demonstration of clinical (bleeding) and laboratory (prothrombin time, activated partial thromboplastin time) resolution with, and relapse ...
Jenny Reeve, Aiden Pang
wiley   +1 more source

Characterization of a PNLIP variant identified in Amish pediatric patients with congenital pancreatic lipase deficiency. [PDF]

open access: yesJ Lipid Res
Curry GE   +10 more
europepmc   +1 more source

Structure-activity relationship of dietary flavonoids on pancreatic lipase. [PDF]

open access: yesCurr Res Food Sci, 2023
Li MM   +5 more
europepmc   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton   +9 more
wiley   +1 more source

A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1160-1167, February 2026.
Abstract Aims Targeting the glucose dependent insulinotropic polypeptide receptor (GIPR) is of growing interest for treating type 2 diabetes and obesity, though the optimal approach remains unclear. Both GIPR agonism and antagonism, respectively, incorporated into drugs like tirzepatide and maridebart cafraglutide, have paradoxically both shown ...
Iona Davies   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy